Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

ArcticZymes Technologies

Less than 1K followers

AZT

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

ArcticZymes Technologies is a biotechnology company. The company specializes in the research and development of pharmaceuticals for the treatment of immune diseases. The main focus is on the development of glucans, the development of immune-stimulating agents, and the analysis of enzymes. The vision is to test and develop the medicine and then pass these on in use for RNA and DNA processes. ArcticZymes Technologies previously went by the name Biotec Pharmacon and is headquartered in Tromsö.

Read more
Market cap
-
Turnover
-
Revenue
104.35M
EBIT %
-1.27 %
P/E
-
Dividend yield-%
-
Financial calendar
27/5
2025

General meeting '25

14/8
2025

Interim report Q2'25

6/11
2025

Interim report Q3'25

All
Press releases
ShowingAll content types
Regulatory press release5/8/2025, 5:00 AM

AZT: ArcticZymes Technologies announces Q1 2025 Financial results. Record Customer Base Growth Lays Foundation for Long-Term Expansion

ArcticZymes Technologies
Regulatory press release5/8/2025, 5:00 AM

ArcticZymes Technologies announces Q1 2025 Financial results. Record Customer Base Growth Lays Foundation for Long-Term Expansion

ArcticZymes Technologies
Regulatory press release5/6/2025, 11:00 AM

ArcticZymes Technologies ASA: Notice of Annual General Meeting

ArcticZymes Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/6/2025, 11:00 AM

ArcticZymes Technologies ASA: Notice of Annual General Meeting

ArcticZymes Technologies
Regulatory press release5/2/2025, 6:31 AM

ArcticZymes Technologies ASA: Invitation to presentation of Q1 2025 results

ArcticZymes Technologies
Regulatory press release4/30/2025, 4:00 PM

ArcticZymes Technologies ASA - Annual Report and ESG report for 2024

ArcticZymes Technologies
Regulatory press release4/30/2025, 4:00 PM

ArcticZymes Technologies ASA - Annual Report and ESG report for 2024

ArcticZymes Technologies
Regulatory press release4/27/2025, 8:09 PM

AZT: Financial calendar

ArcticZymes Technologies
Regulatory press release2/13/2025, 6:00 AM

AZT: ArcticZymes Technologies announces Q4 2024 Financial results

ArcticZymes Technologies
Regulatory press release2/13/2025, 6:00 AM

ArcticZymes Technologies announces Q4 2024 Financial results

ArcticZymes Technologies
Regulatory press release2/6/2025, 1:15 PM

ArcticZymes Technologies ASA: Invitation to presentation of Q4 and 12M 2024 results

ArcticZymes Technologies
Regulatory press release12/18/2024, 7:00 AM

Long-Term Incentive Plan - grant of share options to primary insiders

ArcticZymes Technologies
Regulatory press release12/18/2024, 7:00 AM

ArcticZymes Technologies: Long-Term Incentive Plan - grant of share options to primary insiders

ArcticZymes Technologies
Regulatory press release12/9/2024, 8:00 AM

AZT: ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

ArcticZymes Technologies
Press release12/9/2024, 8:00 AM

ArcticZymes Technologies: ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

ArcticZymes Technologies
Regulatory press release12/3/2024, 1:52 PM

AZT: Financial calendar

ArcticZymes Technologies
Regulatory press release11/21/2024, 11:05 AM

AZT: ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance and High Recovery Rates

ArcticZymes Technologies
Press release11/21/2024, 11:05 AM

ArcticZymes Technologies: ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance and High Recovery Rates

ArcticZymes Technologies
Regulatory press release11/20/2024, 10:25 AM

AZT: ArcticZymes Technologies ASA to present at SEB Healthcare Seminar 2024

ArcticZymes Technologies
Press release11/20/2024, 10:25 AM

ArcticZymes Technologies ASA to present at SEB Healthcare Seminar 2024

ArcticZymes Technologies
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team